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-e inhalation route is frequently used to administer drugs for the management of respiratory diseases such as asthma or chronic
obstructive pulmonary disease. Compared with other routes of administration, inhalation oﬀers a number of advantages in the
treatment of these diseases. For example, via inhalation, a drug is directly delivered to the target organ, conferring high pulmonary
drug concentrations and low systemic drug concentrations.-erefore, drug inhalation is typically associated with high pulmonary
eﬃcacy and minimal systemic side eﬀects. -e lung, as a target, represents an organ with a complex structure and multiple
pulmonary-speciﬁc pharmacokinetic processes, including (1) drug particle/droplet deposition; (2) pulmonary drug dissolution;
(3) mucociliary and macrophage clearance; (4) absorption to lung tissue; (5) pulmonary tissue retention and tissue metabolism;
and (6) absorptive drug clearance to the systemic perfusion. In this review, we describe these pharmacokinetic processes and
explain how theymay be inﬂuenced by drug-, formulation- and device-, and patient-related factors. Furthermore, we highlight the
complex interplay between these processes and describe, using the examples of inhaled albuterol, ﬂuticasone propionate,
budesonide, and olodaterol, how various sequential or parallel pulmonary processes should be considered in order to comprehend
the pulmonary fate of inhaled drugs.
1. Introduction
Inhalation therapy has gained importance in recent decades
[1]. Today, inhalation represents the administration route of
choice for the delivery of drugs to treat respiratory disorders
such as asthma and chronic obstructive pulmonary disease
(COPD) [2–4]. -e inhalation route is also being investigated
in some instances for the systemic delivery of drugs [5, 6].
However, this review will focus on the inhalation route for
local treatment of pulmonary diseases.
-e primary goal of inhalation therapy for local treat-
ment is to reduce pulmonary symptoms, for example,
through the alleviation and/or prevention of airway in-
ﬂammation and constriction [7]. Typical examples of in-
haled drugs are corticosteroids, beta-sympathomimetics,
muscarinic antagonists, and antibiotics. -e inhalation of
these drugs oﬀers substantial beneﬁts over their systemically
administered formulations. Crucially, high pulmonary drug
concentrations can be achieved by directly delivering the
drug to the target organ, the lung. As a result, considerably
lower inhaled doses can be therapeutically equivalent or
even superior to higher doses of systemically administered
therapy [8, 9]. High pulmonary yet low systemic drug
concentrations conferred by inhalation lead to high pul-
monary eﬃcacy, while simultaneously reducing the risk of
side eﬀects. -is means that higher systemic side eﬀects are
typically associated with orally or intravenously adminis-
tered doses that would provide similar pulmonary eﬃcacy
compared with inhalation [7, 8, 10]. In addition to this
favorable pulmonary eﬃcacy to systemic safety ratio
(“pharmacodynamic (PD) airway selectivity”), inhalation
can provide a more rapid onset of eﬀect in the lung than
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other routes of administration (within minutes for albuterol
and up to half an hour for salmeterol) [11–13].
It is typically assumed that the concentration of a drug at
its site of action determines eﬃcacy. In the case of inhaled
drugs for local treatment, this should mean that pulmonary
concentrations drive eﬃcacy. However, it is important to
highlight that the lung should not be considered as a single,
uniform organ; rather, it is an intricate organ with ﬁne,
branched architecture, and various specialized morphologic
structures, including conducting airways, bronchioles, and
alveoli [14, 15]. Due to the complexity of the lung, multiple
pharmacokinetic (PK) processes exist that are speciﬁc to the
pulmonary environment and the inhalation route, making
pulmonary PK generally distinct and much more complex
than those of drugs administered via other routes [16]. Drug
concentrations in the lung are dependent on the interplay
between various pulmonary kinetic processes, examples of
which are outlined later in this review. All pulmonary pro-
cesses are determined, or at least inﬂuenced, by one or more
aspects of the inhaled medication, including physicochemical
characteristics of the drug, drug formulation, and the in-
halation device. Patient characteristics such as competency in
inhalation technique may also impact on pulmonary eﬃcacy
[17]. -erefore, the design of inhaled drugs and development
of inhalation products should be based on a sound un-
derstanding of the totality of all pulmonary PK processes.
Along with pulmonary concentrations, systemic drug con-
centrations must be considered in order to evaluate and
understand the systemic safety proﬁle of an inhaled drug.
However, systemic concentrations depend on a number of
factors, including gastrointestinal absorption of the swallowed
fraction of the drug, the rate and extent of absorption via
pulmonary PK processes, and systemic disposition properties,
such as distribution and elimination.
-is review provides a detailed overview of the factors
aﬀecting drug inhalation and discusses both the speciﬁc pul-
monary and systemic PKproperties of inhaled drugs that ensure
optimal performance. In addition, wewill summarize important
clinical examples (albuterol, ﬂuticasone propionate/budesonide,
and olodaterol) that clearly demonstrate the complex interplay
between pulmonary PK processes and factors related to the
drug, formulation and device, and patients.
2. Pulmonary Pharmacokinetic
Processes following Inhalation in Contrast to
Oral/Intravenous Administration
Traditional methods of administration, such as the oral and
intravenous (IV) routes, have distinct PK considerations.
Oral drugs must pass through the gastrointestinal tract, the
portal vein, and the liver prior to absorption into the sys-
temic circulation. -erefore, the rate and extent of ab-
sorption is initially inﬂuenced by the dissolution kinetics and
the solubility in gastrointestinal ﬂuid. After dissolution, the
intestinal metabolism, passive permeability, and transporter
aﬃnity (eﬄux/active uptake) of the drug determine the
uptake across the intestinal membrane. Last but not least, the
transport in the portal vein, as well as metabolic and
transporter capacity in hepatocytes, determines the systemic
bioavailability of orally administered drugs (hepatic ﬁrst
pass) [18]. In contrast, IV administration involves injection
or infusion of drug molecules directly into the blood vessels,
thereby bypassing the gastrointestinal absorption step and
the intestinal and hepatic ﬁrst pass eﬀects [19]. After either
oral or IV administration, the target is often not located in
the blood or plasma, and so the drug must distribute to the
target organ, such as the lung in respiratory diseases.-erefore,
after systemic administration, the plasma concentration-time
proﬁle is often considered as a surrogate concentration-time
proﬁle for the target organ and target site in the organ [20].
No drug transporters or relevant barriers between blood
and the lung tissue are known, implying that free pul-
monary concentrations are not higher than that in plasma;
hence, pulmonary PK selectivity cannot be achieved by
systemic administration.
-e pulmonary PK processes after drug inhalation con-
trast to those following systemic administration and comprise
(1) drug particle or droplet deposition; (2) drug dissolution in
the lung ﬂuids; (3) mucociliary clearance in the conducting
airways and macrophage clearance in the alveolar space; (4)
absorption (of dissolved drug) to the lung tissue; (5) pul-
monary tissue retention and potential pulmonary metabolism;
and (6) absorptive drug clearance (drug transport) from the
lung tissue to the systemic perfusion. -e interplay between
these processes is outlined in Figure 1 and will be further
discussed later in the review. In addition to the complexity
associated with the pulmonary PK processes, inhaled drugs
present a challenge in that the quantiﬁcation of pulmonary
tissue concentrations by lungmicrodialysis, for example, is not
feasible in a standard clinical setting. Given the multiple ab-
sorption processes following drug inhalation, plasma con-
centrations do not guarantee an easily interpretable surrogate
concentration for pulmonary concentrations and PK pro-
cesses. Rather, the plasma concentration of an inhaled drug is
the result of drug absorption from diﬀerent areas of the lung
and gastrointestinal tract, as well as systemic drug disposition
kinetics. Depending on a drug’s physicochemical properties
and ﬁrst passmetabolism, absorption from the gastrointestinal
tract can be particularly important when a signiﬁcant fraction
of inhaled drug gets swallowed. Overall, characterizing the PK
of inhaled drugs is highly complex because both the pul-
monary and systemic PK have to be simultaneously evaluated.
2.1. Step 1:DrugParticle/DropletDeposition. As summarized
in Figure 1, the ﬁrst process following inhalation is the
deposition of drug particles or droplets. A fraction of the
dose gets deposited in the device, whereas the remaining
fraction of particles or droplets gets delivered to the re-
spiratory system. As particles travel through the airway
geometry, deposition occurs in the mouth-throat region, the
conducting airways, and/or the alveolar space. -e total
fraction deposited in the lung is typically referred to as the
“lung dose”, whereas the pulmonary deposition patterns are
often described as being central (larger airways) or pe-
ripheral (smaller airways + alveolar space). Both the lung
dose and the pulmonary deposition patterns are dependent
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on aerodynamic particle size, inhalation ow, device char-
acteristics, and disease-related factors [10, 21–23] but are
generally independent of the physicochemical characteristics
of the drug itself [21] (Figure 2). Particles or droplets that fail
to reach the lung and deposit in the mouth-throat region are
subsequently swallowed [24, 25], whereas particles that
reach the lung but fail to deposit are exhaled [10].
One fundamental property that determines whether
drug is deposited in the mouth-throat region or the airways
is the aerodynamic particle diameter [21, 26]. Specically,
drug particles with an aerodynamic diameter of approxi-
mately 0.5–5 µm have the greatest potential to be deposited
in the lung (Figure 3). Smaller particles generally deposit
more peripherally in the lung, such as in the alveolar space,
whereas larger particles deposit more centrally, for ex-
ample, in the large conducting airways. Particles larger than
5 µm tend to deposit in the mouth-throat area [27], thereby
reducing the lung dose. Deposition of larger particles in the
central proximal airways and mouth-throat region is
a result of inertial impaction, whereby maximum airow
velocity causes high mass particles to impact [28, 29].
Smaller particles are subject to sedimentation by gravity;
this is the most eective mechanism of deposition in the
small peripheral airways and can be enhanced by breath-
hold following inhalation [21, 29]. Diusional deposition,
or Brownian motion, is most relevant to very small, sub-
micron particles that deposit in the small airways and
alveoli [21, 28].
Innovative inhalation devices have been designed to emit
small particles (1–5 µm aerodynamic diameter), thus max-
imizing the lung dose and the proportion of particles that are
successfully delivered to their target site [30]. Inhalation ow
and the velocity at which aerosol particles are emitted from
a device and travel through the airways also have a strong
impact on pulmonary deposition patterns. Generally, faster
inhalation results in increased central and mouth-throat
region deposition, whereas slower inhalation results in
more peripheral deposition patterns. However, when using
a low-resistance dry-powder inhaler, slow inhalation ow
may be insucient to disaggregate the powdered drug and
can therefore limit lung deposition [31]. Overall, a design
strategy for the inhalation device that couples slow-moving
aerosol with smaller drug particles/droplets has so far been
demonstrated as the most eective method in terms of total
lung deposition and distal airway penetration [28, 32, 33].
2.2. Step 2: Pulmonary Drug Dissolution. Drug particles that
have successfully deposited in the lungmust dissolve into the
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Figure 1: Summary of the lung-specic PK processes for inhaled drugs. Overview of the pulmonary-specic kinetic processes (1–6). e
direction of the arrows indicates the direction of each process. For example, drug dissolution is considered to be a unidirectional process.
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process is dependent on drug formulation, physicochemical
drug properties, and physiologic factors [25]. -e con-
ducting airways are lined with a biphasic gel-aqueous mucus
layer, whereas alveoli are lined with alveolar lining ﬂuid and
pulmonary surfactant [34]. Both the thickness of the pul-
monary lining ﬂuid, which decreases from large to small
airways [35], and its constitution can inﬂuence drug
dissolution. While a mucus layer can act as a barrier to drug
particles [36], surfactants produced by alveolar cells reduce
surface tension and facilitate dissolution [37].
Pulmonary dissolution into the epithelial lining ﬂuid,
which is required for absorption, is also dependent on the
properties of the inhaled drug [25]. While free, solubilized
drugs may diﬀuse rapidly into the pulmonary lining ﬂuid,





















Figure 2: Schematic overview of the interplay of device and formulation, drug, and patient characteristics. -e overlapping areas represent
processes or parameters that are inﬂuenced or determined by the drug, the formulation/device, or the patient characteristics.
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Figure 3: Particle size determines location of drug deposition. Aerodynamic particle size determines deposition patterns across the human
respiratory tract. Simulations were performed using Multiple-Path Particle Dosimetry software [95]. Each simulated particle size represents
one simulation. -e Yeh/Schum ﬁve-lobe model [96] with uniform expansion was applied. -e inhalation characteristics used for the
simulation were an inhaled volume of 2 L, an inhalation ﬂow rate of 60 L/min, and a breath-holding time of 8 seconds.-ese simulations do
not account for the inﬂuence of an inhalation device on deposition.
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dissolution characteristics are crucial for the absorption of
drug deposited as particulate matter. Slow dissolution as
a rate-limiting step can be desirable in that it prolongs lung
retention and eﬀect duration, albeit with a concomitant
increase in the probability that drug particles get cleared by
mucociliary clearance. For example, ﬂuticasone, an inhaled
corticosteroid, is a very hydrophobic drug characterized by
slow dissolution kinetics that oﬀers extended lung retention
and long-lasting pulmonary eﬃcacy [38–40]. In contrast,
albuterol, a short-acting β2-agonist (SABA), is an example of
a drug with high aqueous solubility and a faster pulmonary
dissolution rate [41]. -e desired dissolution proﬁle there-
fore can inﬂuence the design of the drug formulation and the
respective inhalation device.
2.3. Step 3:MucociliaryClearance andMacrophageClearance.
-e pulmonary bioavailability of deposited drug particles
depends on several aspects, including the deposited lung
dose and lung-speciﬁc clearance processes. In the con-
ducting airways, the removal of drug particles is primarily
achieved through mucociliary clearance, an evolutionary
pulmonary protection mechanism against bacteria and dust
particles. Here, the upward movement of mucus is driven by
the beating of underlying cilia towards the pharynx. Drug
particles transported to the pharynx via mucociliary clear-
ance are subsequently swallowed and pass into the gastro-
intestinal tract [42]. Given that the velocity of mucociliary
clearance increases with a wider airway diameter and thicker
mucus layer, this process is fastest in the large airways [43].
-erefore, drug particles initially deposited in the central
airways are cleared most quickly. Drug initially deposited in
the peripheral conducting airways may be transported up-
wards and become available for absorption in the central
airways. -is process may confer long-term eﬃcacy in the
upper airways despite the rapid removal of drug particles
from this region. In patients, the mucociliary clearance
might be decreased due to increased thickness of the mucus
layer or a higher mucus viscosity [44, 45]. In summary, the
relevance of the mucociliary clearance is highly complex,
being inﬂuenced by all the formulation, the drug charac-
teristics, and the patient characteristics (Figure 2).
Particle clearance may also occur from the alveoli, where
deposited particles can be phagocytosed by alveolar macro-
phages and cleared by transport to the lung-draining lymph
nodes [46, 47]. Compared with mucociliary clearance, mac-
rophage clearance of drug particles is far slower [48–50].
-erefore, macrophage clearance is typically assumed to be
negligible for inhaled drugs, which dissolve before being
cleared by this mechanism unless the drug is degraded by
alveolar macrophages [25].
2.4. Step 4: Absorption to Lung Tissue. Drug particles that
successfully evade pulmonary clearance mechanisms and
dissolve in the epithelial lining ﬂuid may then be absorbed
into the lung tissue, a process that is proposed to occur by
several mechanisms. -e absorption through pulmonary
barriers depends on both patient-speciﬁc airway characteristics
and drug characteristics (Figure 2). Lipophilic drugs are
thought to be rapidly absorbed after dissolution by passive
transcellular diﬀusion through epithelial cells [51]. For small
hydrophilic compounds, paracellular diﬀusion across the ep-
itheliummay occur through aqueous pores in intercellular gap
junctions [51, 52]. Particles may also be absorbed through
pores in the epithelium that arise transiently due to apoptosis
[51]. Physiologic characteristics of the pulmonary environment
may further inﬂuence pulmonary absorption (Figure 4). For
instance, drug absorption takes place over an enormous surface
area in the alveolar space but across a smaller surface in the
conducting airways [10]. -e very high perfusion of the al-
veolar space in comparison to the conducting airways also
promotes a higher absorption rate in the alveolar space [10, 51].
Last but not least, an increased absorption rate in the alveolar
space is conferred by the 0.2µm-thick epithelial cell mono-
layer, which is much thinner in comparison with the con-
ducting airways [10, 53]. Overall, absorption of dissolved drug







Figure 4: Summary of pulmonary absorption kinetics based on local physiologic characteristics of respiratory tract regions.
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airways due to diﬀerences in surface area, perfusion, and
epithelial thickness [10, 53–56].
2.5. Step 5: Pulmonary Tissue Retention and Tissue
Metabolism. Pulmonary tissue retention and distribution
of absorbed/dissolved drug in the airways may be inﬂuenced
by the physicochemical drug characteristics [57, 58] of in-
haled drugs or patient-speciﬁc characteristics of airways
(Figure 2). -e tissue aﬃnity, or pulmonary tissue partition
coeﬃcient, of an inhaled drug is likely the most important of
these characteristics [25]. For example, basic drug molecules
are reported to be retained in the lung by lysosomal trapping
[58–60]. -e low permeability of inhaled drugs such as long-
acting muscarinic receptor antagonists (LAMAs) or long-
acting β2-agonists (LABAs) is also considered to result in
long lung retention [58, 60–62]. Further potential mecha-
nisms that may increase pulmonary retention time include
slow receptor oﬀ-kinetics [26, 63, 64], esteriﬁcation in the
lung tissue [65], and interaction with membrane lipid bi-
layers, the latter of which is proposed to account for the long
duration of bronchodilation provided by the LABAs sal-
meterol and formoterol [66]. A long pulmonary retention
time is desirable for most inhaled drugs to extend the du-
ration of eﬃcacy [26]. In addition to absorption from the
pulmonary tissue into systemic circulation, drug absorbed in
the lung can be redistributed to other regions of the airways
from the systemic perfusion.
-e lung also contains drug-metabolizing enzymes, al-
though metabolic capacity for most enzymes in the lung is
lower compared with the gastrointestinal and hepatic enzyme
capacity [67, 68]. However, there are also enzymes that have
a relevant capacity in the lung, such as CYP 1A1 in smokers
[69, 70] or CYP 2E1 [71].
2.6. Step 6: Absorptive Drug Clearance to the Systemic
Perfusion. -e ﬁnal pulmonary PK process is pulmonary
clearance of drug from the lung tissues to the blood cir-
culation (also known as absorptive clearance), a process that
is heavily dependent on perfusion. -e lung is the highest
perfused organ in the body, as the complete cardiac output
ﬂows through the alveolar vascular bed [72]. Levels of local
perfusion, however, vary between the diﬀerent structures in
the lung and are highest in the alveolar region. Here, the
large absorption area, thin epithelium, and pulmonary cir-
culation supply mean that absorptive clearance occurs more
quickly compared with other regions of the lung [10, 73]. By
contrast, perfusion is much slower in the conducting airways,
which have a smaller surface area available for absorption and
are supplied by the systemic circulation instead of the pul-
monary circulation [72, 73]. In the alveoli, a high perfusion
rate confers rapid equilibration with the systemic circulation
and a very short half-life of drug distribution in this region.
-is was discussed for ﬂuticasone propionate and salmeterol,
resulting in reduced airway selectivity in the alveolar space
compared with the conducting airways [73, 74]. Faster drug
absorption as a general observation in the alveolar space was
suggested by Brown and Schanker [75]. For this reason, and
even though tissue retention in the alveolar space might not be
completely absent, the tissue retention in the alveolar space
was not included in Figure 1. In the tracheobronchial region,
a lower perfusion rate combined with higher tissue retention
oﬀers a longer equilibration time and increased local airway
selectivity [73, 74].
3. Systemic and Pulmonary Pharmacokinetic
Properties of Inhaled Drugs
To minimize systemic exposure after drug inhalation, in-
haled drugs should have low oral bioavailability and high
systemic clearance [76, 77]. High oral bioavailability of an
inhaled drug would result in eﬃcient absorption of swal-
lowed fractions and lead to higher systemic exposure.
-erefore, to maximize airway selectivity, oral bioavailability
should remain low, as this can aﬀect the bioavailable fraction
of swallowed drug and impact negatively on airway selec-
tivity, thereby increasing the risk of systemic side eﬀects. In
addition, the systemic clearance of inhaled drugs should be
high, as drugs with high systemic clearance have lower
systemic exposure and are associated with high airway se-
lectivity [26, 77]. -ese aspects further highlight the diﬀerence
between inhaled drugs and orally administered drugs, as these
are often characterized by a high oral bioavailability and a low
systemic clearance.
It has also been discussed that high plasma protein
binding might reduce initial high free plasma concentrations
after pulmonary drug absorption, which are potentially
associated with systemic adverse eﬀects [78]. However, high
plasma protein binding would likely correlate to lower free
pulmonary concentrations, and so this hypothesis requires
further evaluation.
Overall, inhaled drugs are most eﬀective when they are
designed for, and delivered to, their target location in the
airways. An optimal inhaled drug combined with a well-
designed inhalation device would confer the largest diﬀer-
ence between pulmonary drug concentrations and systemic
drug concentrations.-is diﬀerence is known as (PK) airway
selectivity, a concept that underpins the aim of respiratory
treatment to speciﬁcally target the airways [77]. Ultimately,
airway selectivity should also result in a high pulmonary PD
selectivity. Airway selectivity can be further enhanced by
optimizing particle size, which, as discussed, is a key de-
terminant of the pulmonary regions in which inhaled drugs
are deposited [21, 26–29, 79].
4. Well-Characterized Clinical PK and/or
PD Examples
Drug concentrations in the lung typically cannot be directly
measured. -erefore, to indirectly infer on the pulmonary
concentration-time proﬁles, a combination of PK data after
inhalation, oral and IV administration is required. Fur-
thermore, a mathematical approach to simultaneously in-
tegrate all these data and to infer on the relevant pulmonary
and systemic kinetic processes is required. Often, it can also
be of importance to base these mathematic modelling ap-
proaches not only on in vivo PK data but additionally
consider high-quality in vitro data, for example, about
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pulmonary drug deposition or pulmonary drug dissolution
[80]. Even though this integration of data has provided
valuable insights into the overall pulmonary PK proﬁle for
inhaled drugs, our understanding of the intricacies of the
inhalation route remains more limited in comparison to
traditional oral and IV routes [25].
-ree PK and/or PD examples, namely, (1) albuterol, (2)
ﬂuticasone propionate/budesonide, and (3) olodaterol, will
be discussed in detail below [81–85]. Further PK evaluations
have also been published for inhaled drugs such as glyco-
pyrronium [61], a LAMA, and AZD5423, a nonsteroidal
glucocorticoid receptor modulator [86]. However, these are
beyond the scope of this review.
4.1. Example 1: Pulmonary Eﬃcacy of Inhaled Albuterol.
As outlined before, particle size is a key determinant of
overall drug deposition in the airways and therefore has
a major impact on eﬃcacy [21, 26]. Fine particles, that is, in
the range of 1–5 µm, are typically characterized by a low
mouth-throat deposition and consequently by a high lung
dose. Larger particles are deposited to a higher extent in the
mouth-throat area, and subsequently a higher fraction of the
inhaled drug is swallowed. In a study of monodisperse
albuterol aerosols (1.5, 3.0, and 6.0 µm) in patients with
asthma, improved bronchodilation was achieved with larger
particles that resulted in lower lung doses compared with an
equivalent dose of smaller particles [87]. -is was proposed
to be a result of increased central deposition in the con-
ducting airways, where smooth muscle, the target of β2-
agonists, is prominent. Predicted deposition patterns of the
three investigated particle sizes are highlighted in Figure 3.
-e overall smaller dose deposited in the lung for the 6 µm
sized particles also resulted in a lower systemic exposure.
-is example shows that, while a higher lung dose is typically
considered to improve lung selectivity, a lower lung dose
with an optimal deposition pattern resulted in higher eﬃ-
cacy and lower systemic exposure. In contrast, for idiopathic
pulmonary ﬁbrosis patients, a more peripheral deposition
pattern was considered valuable, as potential targets are
located more peripherally in the lung [88]. However, as
outlined before, it remains to be demonstrated that the
pulmonary selectivity in peripheral areas of the lung can be
suﬃcient for future drug targets. In summary, the local
pulmonary deposition patterns should be optimized with
regard to the target location and the diseased area rather
than just the lung dose or the ﬁne particle fraction.
4.2. Example 2: Pulmonary PK and Eﬃcacy of Inhaled
Corticosteroids. Disease-related factors have been shown to
have strong eﬀects on drug PK and PD behavior. In patients
with obstructive pulmonary diseases (e.g. asthma or COPD),
deposition is typically more central compared with less
obstructed airways in healthy volunteers (Figure 5) [23, 89].
In multiple studies comparing the PK of ﬂuticasone











Figure 5: Inhaled drug particle deposition in healthy versus diseased lungs. Reproduced with permission from Wang et al. [23].
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propionate and budesonide following inhalation by asthma
or COPD patients with healthy volunteers, plasma con-
centrations of ﬂuticasone propionate were lower in asthma
and COPD patients compared with healthy volunteers,
whereas those for budesonide were similar between patients
and healthy volunteers [82–84]. A potential explanation is
the combination of the slow dissolution of ﬂuticasone
propionate combined with a high central deposition in
patients.-is could lead to a higher fraction of the drug to be
cleared by the mucociliary clearance in patients compared
with healthy volunteers, and consequently, a lower fraction
of deposited drug being absorbed in the lung. For bron-
chodilating drugs or quickly dissolving corticosteroids, as in
this case budesonide, the diﬀerence in pulmonary PK and
resulting systemic concentrations is less pronounced [82, 85].
-ese drugs dissolve faster in the lung ﬂuids compared with
ﬂuticasone propionate and might, therefore, already be
absorbed to the pulmonary tissue before a substantial amount
of particles can be cleared by the mucociliary clearance. -is
would also result in a higher fraction of the initially deposited
lung dose being available in a dissolved state at the target site.
-ese ﬁndings suggest superior availability of budesonide
compared with ﬂuticasone propionate in acute asthma, in
which the airways are markedly narrowed. -is hypothesis is
supported by the ﬁnding that inhaled ﬂuticasone propionate
confers a poor response in children with acute severe asthma
[90]. On ﬁrst sight, this might be surprising given that ﬂu-
ticasone propionate is considered to be an optimized drug for
inhalation. Furthermore, the higher cleared fraction of ﬂuti-
casone propionate in patients compared with healthy vol-
unteers might be unexpected given that mucociliary clearance
is typically slower in patients with airway diseases [91].
4.3. Example 3: Pulmonary PK of Inhaled Olodaterol.
Olodaterol is another inhaled drug reported to have interesting
PK characteristics in patients. -e impact of asthma and
COPD on the pulmonary PK characteristics of olodaterol was
evaluated in a population PK analysis. Here, despite the de-
creased lung function in asthma and COPD patients, pul-
monary bioavailable fractions of inhaled olodaterol were
comparable with healthy volunteers [85]. Although this result
is consistent with the established lung dose for the soft mist
inhaler used [92], overall pulmonary absorption was slower in
patients [85].-is is unexpected given that airway epithelia are
typically damaged in asthma patients [93], and the integrity of
tight junctions is compromised in COPD patients [94]. -e
overall slower absorption was discussed to be a result of the
more central deposition in patients, which confers an extended
pulmonary residence time. -is suggests preferable lung
targeting of inhaled olodaterol in asthma and COPD patients
compared with healthy volunteers [85].
5. Conclusion
Inhaled drugs are the mainstay of treatment in the care of
pulmonary diseases such as asthma and COPD [2–4].
Compared with other routes of administration, respiratory
drugs that are speciﬁcally designed for inhalation can oﬀer
signiﬁcant beneﬁts, including direct delivery to the disease
target site, rapid onset of action, high and long-term pul-
monary eﬃcacy, and reduced risk of systemic side eﬀects [7].
-ese beneﬁts can be achieved in drug design by considering
the physiochemical properties of inhaled drugs (e.g., solubility),
the device and formulation characteristics (e.g., particle size),
and also the inﬂuence of patient characteristics. Overall,
a sound understanding of the lung and its associated kinetic
processes is necessary to overcome the complex challenges of
the inhalational route of administration. Furthermore, the
interplay between all pulmonary kinetic processes is highly
complex. All pulmonary kinetic processes must be simulta-
neously considered as consideration of only a single process or
parameter, such as lung dose, can lead to incorrect assumptions
or inferences regarding pulmonary eﬃcacy of inhaled drugs.
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